This Article Full Text Full Text (PDF) Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hartley, A Articles by Geh, J I Search for Related Content PubMed PubMed Citation Articles by Hartley, A Articles by Geh, J I

Pathological complete response following pre-operative chemoradiotherapy in rectal cancer: analysis of phase II/III trials

¹ Cancer Centre, Queen Elizabeth Hospital, Birmingham B15 2TH and ² Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK

Pathological complete response (pCR) has been used as a marker for the efficacy of pre-operative chemoradiotherapy (CRT) schedules in rectal cancer. To date there have been no randomized trials comparing CRT regimens in rectal cancer. Prospective phase II and CRT arms of randomized trials reported up to January 2004 were included, providing they defined the following minimum variables: drugs employed during CRT, radiotherapy dose and pCR rate. Multivariate analysis was used to examine the relationship of these variables on the pCR rate. In addition, the use of neoadjuvant chemotherapy, the type of publication (peer reviewed vs meeting abstract) and whether the tumours were stated to be unresectable/clinically fixed or to have threatened circumferential margins were investigated. The method of analysis was weighted linear modelling of the pCR rate which was normalized by the arcsine transformation. Phase II and phase III trials were identified including a total of 3157 patients. On multivariate analysis only the use of continuous infusion 5FU (p=0.01), the use of a second drug (p=0.001) and radiation dose (p=0.02) were associated with higher rates of pCR. The use of a two drug regimen, the mode of delivery of 5FU and the radiation dose appear to be related to the incidence of pCR following CRT for rectal cancer. These results may generate hypotheses for future randomized trials. Important factors not considered in this analysis include the variability in pathological examination and in the time interval between CRT and surgery. In addition, the toxicity of the CRT regimens requires further investigation.

This article has been cited by other articles:

				S. H. Kim, J. M. Lee, S. H. Hong, G. H. Kim, J. Y. Lee, J. K. Han, and B. I. Choi Locally Advanced Rectal Cancer: Added Value of Diffusion-weighted MR Imaging in the Evaluation of Tumor Response to Neoadjuvant Chemo- and Radiation Therapy Radiology, October 1, 2009; 253(1): 116 - 125. [Abstract] [Full Text] [PDF]

				N. Methy, L. Bedenne, T. Conroy, O. Bouche, O. Chapet, M. Ducreux, J.-P. Gerard, and F. Bonnetain Surrogate end points for overall survival and local control in neoadjuvant rectal cancer trials: statistical evaluation based on the FFCD 9203 trial Ann. Onc., September 16, 2009; (2009) mdp340v1. [Abstract] [Full Text] [PDF]

				C. Carlomagno, A. Farella, L. Bucci, F. P. D'Armiento, G. Pesce, S. Pepe, L. Cannella, R. Pacelli, A. De Stefano, R. Solla, et al. Neo-adjuvant treatment of rectal cancer with capecitabine and oxaliplatin in combination with radiotherapy: a phase II study Ann. Onc., May 1, 2009; 20(5): 906 - 912. [Abstract] [Full Text] [PDF]

				R. F. A. Vliegen, G. L. Beets, G. Lammering, R. C. Dresen, H. J. Rutten, A. G. Kessels, T.-K. Oei, A. P. de Bruine, J. M. A. van Engelshoven, and R. G. H. Beets-Tan Mesorectal Fascia Invasion after Neoadjuvant Chemotherapy and Radiation Therapy for Locally Advanced Rectal Cancer: Accuracy of MR Imaging for Prediction Radiology, February 1, 2008; 246(2): 454 - 462. [Abstract] [Full Text] [PDF]

				C. Aschele and S. Lonardi Multidisciplinary treatment of rectal cancer: medical oncology. Ann. Onc., November 1, 2007; 18(11): 1908 - 1915. [Full Text] [PDF]

				R. Glynne-Jones and M. Harrison Locally Advanced Rectal Cancer: What Is the Evidence for Induction Chemoradiation? Oncologist, November 1, 2007; 12(11): 1309 - 1318. [Abstract] [Full Text] [PDF]

				I. Chau, D. Cunningham, D. Tait, and G. Brown In Reply J. Clin. Oncol., October 1, 2006; 24(28): 4665 - 4666. [Full Text] [PDF]

				R. Glynne-Jones, S. Mawdsley, T. Pearce, and M. Buyse Alternative clinical end points in rectal cancer--are we getting closer? Ann. Onc., August 1, 2006; 17(8): 1239 - 1248. [Abstract] [Full Text] [PDF]